Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurofeedback vs Varenicline for Smoking Cessation
NCT02991781Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Countries
- 3
01
Overview
Randomised, single-blind trial (4 arms), sponsored by Aristotle University of Thessaloniki. Primary endpoint: Neurofeedback vs. Varenicline efficacy for smoking cessation at 2 years. Started Jan 2017; status: completed.
Beyond the preview
Go deeper on NCT02991781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991781.